{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T22:02:13Z","timestamp":1794434533465,"version":"4.9.1"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T00:00:00Z","timestamp":1701734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T00:00:00Z","timestamp":1701734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The respiratory system, especially the lung, is the key site of pathological injury induced by SARS-CoV-2 infection. Given the low feasibility of targeted delivery of antibodies into the lungs by intravenous administration and the short half-life period of antibodies in the lungs by intranasal or aerosolized immunization, mRNA encoding broadly neutralizing antibodies with lung-targeting capability can perfectly provide high-titer antibodies in lungs to prevent the SARS-CoV-2 infection. Here, we firstly identify a human monoclonal antibody, 8-9D, with broad neutralizing potency against SARS-CoV-2 variants. The neutralization mechanism of this antibody is explained by the structural characteristics of 8-9D Fabs in complex with the Omicron BA.5 spike. In addition, we evaluate the efficacy of 8-9D using a safe and robust mRNA delivery platform and compare the performance of 8-9D when its mRNA is and is not selectively delivered to the lungs. The lung-selective delivery of the 8-9D mRNA enables the expression of neutralizing antibodies in the lungs which blocks the invasion of the virus, thus effectively protecting female K18-hACE2 transgenic mice from challenge with the Beta or Omicron BA.1 variant. Our work underscores the potential application of lung-selective mRNA antibodies in the prevention and treatment of infections caused by circulating SARS-CoV-2 variants.<\/jats:p>","DOI":"10.1038\/s41467-023-43798-8","type":"journal-article","created":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T12:02:22Z","timestamp":1701777742000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["A lung-selective delivery of mRNA encoding broadly neutralizing antibody against SARS-CoV-2 infection"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9864-8993","authenticated-orcid":false,"given":"Wanbo","family":"Tai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5531-6972","authenticated-orcid":false,"given":"Yubin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruofan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyong","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjie","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaolong","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huicheng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhida","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enhao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongyu","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5185-4781","authenticated-orcid":false,"given":"Yunfeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0360-3635","authenticated-orcid":false,"given":"Mingyao","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0230-9522","authenticated-orcid":false,"given":"Ye","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1157-4184","authenticated-orcid":false,"given":"Guocan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7447-5488","authenticated-orcid":false,"given":"Gong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,5]]},"reference":[{"key":"43798_CR1","unstructured":"WHO. WHO Coronavirus (COVID-19) Dashboard. https:\/\/covid19.who.int (2023)."},{"key":"43798_CR2","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1473-3099(21)00224-3","volume":"21","author":"C Menni","year":"2021","unstructured":"Menni, C. et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect. Dis. 21, 939\u2013949 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"43798_CR3","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"43798_CR4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99\u2013111 (2021).","journal-title":"Lancet"},{"key":"43798_CR5","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S0140-6736(20)31866-3","volume":"396","author":"DY Logunov","year":"2020","unstructured":"Logunov, D. Y. et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1\/2 studies from Russia. Lancet 396, 887\u2013897 (2020).","journal-title":"Lancet"},{"key":"43798_CR6","first-page":"30","volume":"2","author":"LZ Li J","year":"2022","unstructured":"Li J, L. Z., Zhu, Y., Zhou, L. & Zhu, F. Evidence of the efficacy and the effectiveness of first generation COVID-19 vaccines in clinical trials and real-world studies. Zoonoses 2, 30 (2022).","journal-title":"Zoonoses"},{"key":"43798_CR7","doi-asserted-by":"publisher","first-page":"110337","DOI":"10.1016\/j.biopha.2020.110337","volume":"129","author":"L Jahanshahlu","year":"2020","unstructured":"Jahanshahlu, L. & Rezaei, N. Monoclonal antibody as a potential anti-COVID-19. Biomed. Pharmacother. 129, 110337 (2020).","journal-title":"Biomed. Pharmacother."},{"key":"43798_CR8","first-page":"95","volume":"3","author":"X Zeng","year":"2020","unstructured":"Zeng, X. et al. Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy. Antib. Ther. 3, 95\u2013100 (2020).","journal-title":"Antib. Ther."},{"key":"43798_CR9","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41586-020-2381-y","volume":"584","author":"R Shi","year":"2020","unstructured":"Shi, R. et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature 584, 120\u2013124 (2020).","journal-title":"Nature"},{"key":"43798_CR10","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","volume":"583","author":"D Pinto","year":"2020","unstructured":"Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583, 290\u2013295 (2020).","journal-title":"Nature"},{"key":"43798_CR11","doi-asserted-by":"publisher","first-page":"104820","DOI":"10.1016\/j.antiviral.2020.104820","volume":"179","author":"W Tai","year":"2020","unstructured":"Tai, W. et al. Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2. Antivir. Res. 179, 104820 (2020).","journal-title":"Antivir. Res."},{"key":"43798_CR12","doi-asserted-by":"publisher","first-page":"e440","DOI":"10.1093\/cid\/ciab912","volume":"75","author":"M Dougan","year":"2022","unstructured":"Dougan, M. et al. A randomized, placebo-controlled clinical trial of bamlanivimab and etesevimab together in high-risk ambulatory patients with COVID-19 and validation of the prognostic value of persistently high viral load. Clin. Infect. Dis. 75, e440\u2013e449 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"43798_CR13","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1056\/NEJMoa2108163","volume":"385","author":"DM Weinreich","year":"2021","unstructured":"Weinreich, D. M. et al. REGEN-COV antibody combination and outcomes in outpatients with Covid-19. N. Engl. J. Med. 385, e81 (2021).","journal-title":"N. Engl. J. Med."},{"key":"43798_CR14","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","volume":"385","author":"A Gupta","year":"2021","unstructured":"Gupta, A. et al. Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N. Engl. J. Med. 385, 1941\u20131950 (2021).","journal-title":"N. Engl. J. Med."},{"key":"43798_CR15","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1146\/annurev-immunol-042718-041309","volume":"40","author":"JE Crowe Jr","year":"2022","unstructured":"Crowe, J. E. Jr Human antibodies for viral infections. Annu. Rev. Immunol. 40, 349\u2013386 (2022).","journal-title":"Annu. Rev. Immunol."},{"key":"43798_CR16","doi-asserted-by":"publisher","first-page":"e0286222","DOI":"10.1128\/mbio.02862-22","volume":"13","author":"EM Bloch","year":"2022","unstructured":"Bloch, E. M. et al. The potential role of passive antibody-based therapies as treatments for monkeypox. mBio 13, e0286222 (2022).","journal-title":"mBio"},{"key":"43798_CR17","doi-asserted-by":"publisher","first-page":"1886560","DOI":"10.1080\/21645515.2021.1886560","volume":"18","author":"T Tharmalingam","year":"2022","unstructured":"Tharmalingam, T., Han, X., Wozniak, A. & Saward, L. Polyclonal hyper immunoglobulin: a proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases. Hum. Vaccin Immunother. 18, 1886560 (2022).","journal-title":"Hum. Vaccin Immunother."},{"key":"43798_CR18","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1007\/s12668-022-00997-9","volume":"12","author":"A Kirillova","year":"2022","unstructured":"Kirillova, A., Lado, A. & Blatt, N. Application of monoclonal antibody drugs in treatment of COVID-19: a review. Bionanoscience 12, 1436\u20131454 (2022).","journal-title":"Bionanoscience"},{"key":"43798_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/978-1-0716-1884-4_5","volume":"2410","author":"S Thomas","year":"2022","unstructured":"Thomas, S. & Abraham, A. mRNA vaccines to protect against diseases. Methods Mol. Biol. 2410, 111\u2013129 (2022).","journal-title":"Methods Mol. Biol."},{"key":"43798_CR20","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3390\/v14020401","volume":"14","author":"T Le","year":"2022","unstructured":"Le, T. et al. mRNA vaccine development for emerging animal and zoonotic diseases. Viruses 14, 401 (2022).","journal-title":"Viruses"},{"key":"43798_CR21","doi-asserted-by":"publisher","unstructured":"You, H. et al. The mRNA vaccine technology era and the future control of parasitic infections. Clin. Microbiol. Rev. https:\/\/doi.org\/10.1128\/cmr.00241-21e0024121 (2023).","DOI":"10.1128\/cmr.00241-21e0024121"},{"key":"43798_CR22","doi-asserted-by":"publisher","first-page":"eadc9937","DOI":"10.1126\/sciadv.adc9937","volume":"8","author":"K van de Ven","year":"2022","unstructured":"van de Ven, K. et al. A universal influenza mRNA vaccine candidate boosts T cell responses and reduces zoonotic influenza virus disease in ferrets. Sci. Adv. 8, eadc9937 (2022).","journal-title":"Sci. Adv."},{"key":"43798_CR23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cytogfr.2022.10.001","volume":"68","author":"X Qiu","year":"2022","unstructured":"Qiu, X. et al. Development of mRNA vaccines against respiratory syncytial virus (RSV). Cytokine Growth Factor Rev. 68, 37\u201353 (2022).","journal-title":"Cytokine Growth Factor Rev."},{"key":"43798_CR24","doi-asserted-by":"publisher","first-page":"e2206333119","DOI":"10.1073\/pnas.2206333119","volume":"119","author":"M McMahon","year":"2022","unstructured":"McMahon, M. et al. Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses. Proc. Natl Acad. Sci. USA 119, e2206333119 (2022).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"43798_CR25","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","volume":"20","author":"N Chaudhary","year":"2021","unstructured":"Chaudhary, N., Weissman, D. & Whitehead, K. A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat. Rev. Drug Discov. 20, 817\u2013838 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"43798_CR26","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1038\/s41591-021-01574-5","volume":"27","author":"P Zhang","year":"2021","unstructured":"Zhang, P. et al. A multiclade env-gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques. Nat. Med. 27, 2234\u20132245 (2021).","journal-title":"Nat. Med."},{"key":"43798_CR27","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3390\/pharmaceutics15010166","volume":"15","author":"T Vavilis","year":"2023","unstructured":"Vavilis, T. et al. mRNA in the context of protein replacement therapy. Pharmaceutics 15, 166 (2023).","journal-title":"Pharmaceutics"},{"key":"43798_CR28","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","volume":"27","author":"PS Kowalski","year":"2019","unstructured":"Kowalski, P. S., Rudra, A., Miao, L. & Anderson, D. G. Delivering the messenger: advances in technologies for therapeutic mRNA delivery. Mol. Ther. 27, 710\u2013728 (2019).","journal-title":"Mol. Ther."},{"key":"43798_CR29","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41587-021-00822-w","volume":"39","author":"EL Blanchard","year":"2021","unstructured":"Blanchard, E. L. et al. Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents. Nat. Biotechnol. 39, 717\u2013726 (2021).","journal-title":"Nat. Biotechnol."},{"key":"43798_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-66775-3","volume":"10","author":"J Cui","year":"2020","unstructured":"Cui, J., Techakriengkrai, N., Nedumpun, T. & Suradhat, S. Abrogation of PRRSV infectivity by CRISPR-Cas13b-mediated viral RNA cleavage in mammalian cells. Sci. Rep. 10, 9617 (2020).","journal-title":"Sci. Rep."},{"key":"43798_CR31","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1126\/science.abm0271","volume":"378","author":"CP Arevalo","year":"2022","unstructured":"Arevalo, C. P. et al. A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes. Science 378, 899\u2013904 (2022).","journal-title":"Science"},{"key":"43798_CR32","first-page":"1365","volume":"326","author":"J Abbasi","year":"2021","unstructured":"Abbasi, J. Moderna\u2019s mRNA vaccine for seasonal flu enters clinical trials. Jama 326, 1365 (2021).","journal-title":"Jama"},{"key":"43798_CR33","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1080\/21645515.2020.1829899","volume":"17","author":"AO Aliprantis","year":"2021","unstructured":"Aliprantis, A. O. et al. A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults. Hum. Vaccin Immunother. 17, 1248\u20131261 (2021).","journal-title":"Hum. Vaccin Immunother."},{"key":"43798_CR34","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/j.vaccine.2020.12.070","volume":"39","author":"C Aldrich","year":"2021","unstructured":"Aldrich, C. et al. Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: a phase 1 trial. Vaccine 39, 1310\u20131318 (2021).","journal-title":"Vaccine"},{"key":"43798_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-019-1804-8","volume":"17","author":"L Van Hoecke","year":"2019","unstructured":"Van Hoecke, L. & Roose, K. How mRNA therapeutics are entering the monoclonal antibody field. J. Transl. Med. 17, 54 (2019).","journal-title":"J. Transl. Med."},{"key":"43798_CR36","doi-asserted-by":"publisher","first-page":"103479","DOI":"10.1016\/j.isci.2021.103479","volume":"24","author":"S Ndeupen","year":"2021","unstructured":"Ndeupen, S. et al. The mRNA-LNP platform\u2019s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience 24, 103479 (2021).","journal-title":"iScience"},{"key":"43798_CR37","doi-asserted-by":"publisher","first-page":"e0018821","DOI":"10.1128\/cmr.00188-21","volume":"35","author":"F Zhao","year":"2022","unstructured":"Zhao, F., Ma, Q., Yue, Q. & Chen, H. SARS-CoV-2 infection and lung regeneration. Clin. Microbiol. Rev. 35, e0018821 (2022).","journal-title":"Clin. Microbiol. Rev."},{"key":"43798_CR38","doi-asserted-by":"publisher","first-page":"109055","DOI":"10.1016\/j.celrep.2021.109055","volume":"35","author":"A Mulay","year":"2021","unstructured":"Mulay, A. et al. SARS-CoV-2 infection of primary human lung epithelium for COVID-19 modeling and drug discovery. Cell Rep. 35, 109055 (2021).","journal-title":"Cell Rep."},{"key":"43798_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37926-7","volume":"14","author":"Y Liu","year":"2023","unstructured":"Liu, Y. et al. Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants. Nat. Commun. 14, 2179 (2023).","journal-title":"Nat. Commun."},{"key":"43798_CR40","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/s41586-020-2852-1","volume":"588","author":"CO Barnes","year":"2020","unstructured":"Barnes, C. O. et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 588, 682\u2013687 (2020).","journal-title":"Nature"},{"key":"43798_CR41","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1126\/science.abc2241","volume":"368","author":"Y Wu","year":"2020","unstructured":"Wu, Y. et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science 368, 1274\u20131278 (2020).","journal-title":"Science"},{"key":"43798_CR42","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1126\/science.abm8143","volume":"375","author":"YJ Park","year":"2022","unstructured":"Park, Y. J. et al. Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry. Science 375, 449\u2013454 (2022).","journal-title":"Science"},{"key":"43798_CR43","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41421-022-00449-4","volume":"8","author":"X Li","year":"2022","unstructured":"Li, X. et al. Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages. Cell Discov. 8, 87 (2022).","journal-title":"Cell Discov."},{"key":"43798_CR44","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","volume":"593","author":"P Wang","year":"2021","unstructured":"Wang, P. et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593, 130\u2013135 (2021).","journal-title":"Nature"},{"key":"43798_CR45","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41590-022-01138-w","volume":"23","author":"Z Li","year":"2022","unstructured":"Li, Z. et al. An engineered bispecific human monoclonal antibody against SARS-CoV-2. Nat. Immunol. 23, 423\u2013430 (2022).","journal-title":"Nat. Immunol."},{"key":"43798_CR46","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41586-022-04980-y","volume":"608","author":"Y Cao","year":"2022","unstructured":"Cao, Y. et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature 608, 593\u2013602 (2022).","journal-title":"Nature"},{"key":"43798_CR47","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","volume":"15","author":"Q Cheng","year":"2020","unstructured":"Cheng, Q. et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat. Nanotechnol. 15, 313\u2013320 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"43798_CR48","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature18300","volume":"534","author":"LM Kranz","year":"2016","unstructured":"Kranz, L. M. et al. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 534, 396\u2013401 (2016).","journal-title":"Nature"},{"key":"43798_CR49","doi-asserted-by":"publisher","first-page":"e2109256118","DOI":"10.1073\/pnas.2109256118","volume":"118","author":"SA Dilliard","year":"2021","unstructured":"Dilliard, S. A., Cheng, Q. & Siegwart, D. J. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. Proc. Natl Acad. Sci. USA 118, e2109256118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"43798_CR50","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1166\/jnn.2016.11667","volume":"16","author":"E Winter","year":"2016","unstructured":"Winter, E., Dal Pizzol, C., Locatelli, C. & Crezkynski-Pasa, T. B. Development and evaluation of lipid nanoparticles for drug delivery: study of toxicity in, vitro and in vivo. J. Nanosci. Nanotechnol. 16, 1321\u20131330 (2016).","journal-title":"J. Nanosci. Nanotechnol."},{"key":"43798_CR51","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jconrel.2006.04.014","volume":"114","author":"H Lv","year":"2006","unstructured":"Lv, H. et al. Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control. Release 114, 100\u2013109 (2006).","journal-title":"J. Control. Release"},{"key":"43798_CR52","unstructured":"WHO. Weekly Epidemiological Update on COVID-19 - 1 September 2023, https:\/\/www.who.int\/publications\/m\/item\/weekly-epidemiological-update-on-covid-19---1-september-2023 (2023)."},{"key":"43798_CR53","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41577-021-00542-x","volume":"21","author":"PC Taylor","year":"2021","unstructured":"Taylor, P. C. et al. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat. Rev. Immunol. 21, 382\u2013393 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"43798_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-021-00784-w","volume":"29","author":"YC Hwang","year":"2022","unstructured":"Hwang, Y. C. et al. Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. J. Biomed. Sci. 29, 1 (2022).","journal-title":"J. Biomed. Sci."},{"key":"43798_CR55","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41586-021-03720-y","volume":"596","author":"RE Chen","year":"2021","unstructured":"Chen, R. E. et al. In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. Nature 596, 103\u2013108 (2021).","journal-title":"Nature"},{"key":"43798_CR56","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41422-022-00630-0","volume":"32","author":"Y-Q Deng","year":"2022","unstructured":"Deng, Y.-Q. et al. Lipid nanoparticle-encapsulated mRNA antibody provides long-term protection against SARS-CoV-2 in mice and hamsters. Cell Res. 32, 375\u2013382 (2022).","journal-title":"Cell Res."},{"key":"43798_CR57","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","volume":"26","author":"S Sabnis","year":"2018","unstructured":"Sabnis, S. et al. A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates. Mol. Ther. 26, 1509\u20131519 (2018).","journal-title":"Mol. Ther."},{"key":"43798_CR58","doi-asserted-by":"publisher","first-page":"100037","DOI":"10.1016\/j.gene.2020.100037","volume":"763s","author":"Y Colon-Cortes","year":"2020","unstructured":"Colon-Cortes, Y., Hasan, M. A. & Aslanidi, G. Intra-tracheal delivery of AAV6 vectors results in sustained transduction in murine lungs without genomic integration. Gene 763s, 100037 (2020).","journal-title":"Gene"},{"key":"43798_CR59","doi-asserted-by":"publisher","first-page":"102","DOI":"10.3390\/pharmaceutics12020102","volume":"12","author":"A Wadhwa","year":"2020","unstructured":"Wadhwa, A. et al. Opportunities and challenges in the delivery of mRNA-based vaccines. Pharmaceutics 12, 102 (2020).","journal-title":"Pharmaceutics"},{"key":"43798_CR60","doi-asserted-by":"publisher","first-page":"122256","DOI":"10.1016\/j.ijpharm.2022.122256","volume":"627","author":"FF Hsu","year":"2022","unstructured":"Hsu, F. F. et al. An efficient approach for SARS-CoV-2 monoclonal antibody production via modified mRNA-LNP immunization. Int J. Pharm. 627, 122256 (2022).","journal-title":"Int J. Pharm."},{"key":"43798_CR61","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3390\/vaccines9020108","volume":"9","author":"CE Deal","year":"2021","unstructured":"Deal, C. E., Carfi, A. & Plante, O. J. Advancements in mRNA encoded antibodies for passive immunotherapy. Vaccines 9, 108 (2021).","journal-title":"Vaccines"},{"key":"43798_CR62","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41392-022-01007-w","volume":"7","author":"S Qin","year":"2022","unstructured":"Qin, S. et al. mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct. Target Ther. 7, 166 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"43798_CR63","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jim.2007.09.017","volume":"329","author":"T Tiller","year":"2008","unstructured":"Tiller, T. et al. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J. Immunol. Methods 329, 112\u2013124 (2008).","journal-title":"J. Immunol. Methods"},{"key":"43798_CR64","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nmeth.1318","volume":"6","author":"DG Gibson","year":"2009","unstructured":"Gibson, D. G. et al. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat. Methods 6, 343\u2013345 (2009).","journal-title":"Nat. Methods"},{"key":"43798_CR65","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/nmeth.4193","volume":"14","author":"SQ Zheng","year":"2017","unstructured":"Zheng, S. Q. et al. MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331\u2013332 (2017).","journal-title":"Nat. Methods"},{"key":"43798_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsb.2015.11.003","volume":"193","author":"K Zhang","year":"2016","unstructured":"Zhang, K. Gctf: Real-time CTF determination and correction. J. Struct. Biol. 193, 1\u201312 (2016).","journal-title":"J. Struct. Biol."},{"key":"43798_CR67","doi-asserted-by":"publisher","first-page":"e42166","DOI":"10.7554\/eLife.42166","volume":"7","author":"J Zivanov","year":"2018","unstructured":"Zivanov, J. et al. New tools for automated high-resolution cryo-EM structure determination in RELION-3. Elife 7, e42166 (2018).","journal-title":"Elife"},{"key":"43798_CR68","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nmeth.4169","volume":"14","author":"A Punjani","year":"2017","unstructured":"Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290\u2013296 (2017).","journal-title":"Nat. Methods"},{"key":"43798_CR69","first-page":"874","volume":"4","author":"R Sanchez-Garcia","year":"2021","unstructured":"Sanchez-Garcia, R. et al. DeepEMhancer: a deep learning solution for cryo-EM volume post-processing. Communications. Biology 4, 874 (2021).","journal-title":"Biology"},{"key":"43798_CR70","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1107\/S0907444904019158","volume":"60","author":"P Emsley","year":"2004","unstructured":"Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr D. Biol. Crystallogr 60, 2126\u20132132 (2004).","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"43798_CR71","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","volume":"66","author":"PD Adams","year":"2010","unstructured":"Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D. Biol. Crystallogr 66, 213\u2013221 (2010).","journal-title":"Acta Crystallogr D. Biol. Crystallogr"},{"key":"43798_CR72","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1107\/S2059798317016035","volume":"74","author":"L Potterton","year":"2018","unstructured":"Potterton, L. et al. CCP4i2: the new graphical user interface to the CCP4 program suite. Acta Crystallogr D. Struct. Biol. 74, 68\u201384 (2018).","journal-title":"Acta Crystallogr D. Struct. Biol."},{"key":"43798_CR73","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/pro.3235","volume":"27","author":"TD Goddard","year":"2018","unstructured":"Goddard, T. D. et al. UCSF ChimeraX: meeting modern challenges in visualization and analysis. Protein Sci. 27, 14\u201325 (2018).","journal-title":"Protein Sci."},{"key":"43798_CR74","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1093\/bioinformatics\/btx283","volume":"33","author":"R Kleffner","year":"2017","unstructured":"Kleffner, R. et al. Foldit Standalone: a video game-derived protein structure manipulation interface using Rosetta. Bioinformatics 33, 2765\u20132767 (2017).","journal-title":"Bioinformatics"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-43798-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-43798-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-43798-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T13:03:43Z","timestamp":1701781423000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-023-43798-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,5]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["43798"],"URL":"https:\/\/doi.org\/10.1038\/s41467-023-43798-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,5]]},"assertion":[{"value":"17 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.Y., G.C., W.T., K.Y., and Y.L. have applied for the patent (202310810894X) related to the lung-selective LNP formulation and its preparation. All other authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8042"}}